On December 1, 2022 Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, reported that the company will participate in the investor-focused Cantor Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference taking place in Miami December 7-8, 2022 (Press release, Akari Therapeutics, DEC 1, 2022, View Source [SID1234624655]). Akari President and CEO Rachelle Jacques will take part in an ophthalmology panel on December 8 at 1:45 pm ET,Vision for the Future: Dry AMD, Other Greenfield Opportunities, and Late-Stage Stories to Shake Things Up. The Akari management team also will attend 1:1 investor meetings at the conference to discuss progress in the promising pre-clinical program that is investigating long-acting PAS-nomacopan in geographic atrophy (GA).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On December 1, 2022 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that Robert E. Hoffman, President and CEO of Kintara, will be participating at the RHK Capital Disruptive Growth Conference in New York City (Press release, Kintara Therapeutics, DEC 1, 2022, View Source [SID1234624653]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The RHK Capital Disruptive Growth Conference will feature leading C-suite executives and senior management of up to 30 growth-oriented and disruptive companies to meet with seasoned institutional investors, accredited investors, representatives of family offices, market analysts and financial advisors, as well as broker-dealer wealth managers, and select RHK clients.

Kintara’s webcast will be held on December 5, 2022 at 2:40 pm ET.

To view Kintara’s webcast please access the following link:

View Source

On December 1, 2022 Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, reported that the Company will present at the Antibody Engineering and Therapeutics Conference, the Antibody Society’s Annual Meeting, to be held in-person in San Diego, CA from December 4-8, 2022 (Press release, Kineta, DEC 1, 2022, View Source;utm_medium=rss&utm_campaign=kineta-to-participate-in-jmp-securities-hematology-and-oncology-summit [SID1234624652]). Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, will give an oral presentation on KVA12123 (formerly referred to as KVA12.1). KVA12123 is the Company’s VISTA blocking immunotherapy that is expected to initiate Phase 1 clinical trials in patients with advanced solid tumors in the fourth quarter of 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Title: KVA12123 (formerly referred to as KVA12.1), a VISTA Blocking Immunotherapy

Presenter: Thierry Guillaudeux, Ph.D.

Date / Time: December 7, 2022, at 8:45 A.M. Pacific Time

Session Type: Oral Presentation

A copy of the presentation will be available on the Kineta website under Publications after the conference on December 7, 2022: View Source

On November 30, 2022 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, reported the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share (Press release, Intellia, DEC 1, 2022, View Source [SID1234624651]). Intellia also granted the underwriter a 30-day option to purchase up to an additional 982,532 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by Intellia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs & Co. LLC is the sole underwriter for the offering. The offering is expected to close on or about December 2, 2022, subject to customary closing conditions.

The shares of common stock are being offered by Intellia pursuant to an effective shelf registration statement, including a prospectus, that was previously filed with the U.S. Securities and Exchange Commission (SEC). The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, from: Goldman Sachs & Co. LLC, by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On December 1, 2022 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, reported that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on Thursday, December 8, 2022 at 2:45 p.m. EST (Press release, IGM Biosciences, DEC 1, 2022, View Source [SID1234624650]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.